CN106109397A - 包含至少一种肾上腺素能化合物的稳定化组合物 - Google Patents
包含至少一种肾上腺素能化合物的稳定化组合物 Download PDFInfo
- Publication number
- CN106109397A CN106109397A CN201610726131.7A CN201610726131A CN106109397A CN 106109397 A CN106109397 A CN 106109397A CN 201610726131 A CN201610726131 A CN 201610726131A CN 106109397 A CN106109397 A CN 106109397A
- Authority
- CN
- China
- Prior art keywords
- adrenergic compounds
- antioxidant
- range
- composition
- pyrosulfite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 127
- 230000001800 adrenalinergic effect Effects 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 93
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 91
- -1 sulfite compound Chemical class 0.000 claims abstract description 79
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims abstract description 48
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 89
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 87
- 229960005139 epinephrine Drugs 0.000 claims description 87
- 239000003814 drug Substances 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 27
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 19
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 16
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 208000003455 anaphylaxis Diseases 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 9
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 230000001590 oxidative effect Effects 0.000 claims description 8
- 210000004100 adrenal gland Anatomy 0.000 claims description 7
- 239000007800 oxidant agent Substances 0.000 claims description 7
- 235000010265 sodium sulphite Nutrition 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 238000003149 assay kit Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 description 69
- 239000000243 solution Substances 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 13
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 12
- 239000012535 impurity Substances 0.000 description 12
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- WBZKQQHYRPRKNJ-UHFFFAOYSA-N disulfurous acid Chemical compound OS(=O)S(O)(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-N 0.000 description 9
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 9
- 230000008646 thermal stress Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000003943 catecholamines Chemical class 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940039009 isoproterenol Drugs 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 5
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 5
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960002896 clonidine Drugs 0.000 description 5
- 229960001022 fenoterol Drugs 0.000 description 5
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 5
- 229960000195 terbutaline Drugs 0.000 description 5
- 229940035024 thioglycerol Drugs 0.000 description 5
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 238000006701 autoxidation reaction Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960001089 dobutamine Drugs 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GEFQWZLICWMTKF-CDUCUWFYSA-N (-)-alpha-Methylnoradrenaline Chemical compound C[C@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 GEFQWZLICWMTKF-CDUCUWFYSA-N 0.000 description 3
- IOVGROKTTNBUGK-SJKOYZFVSA-N (1S,2R)-ritodrine Chemical compound N([C@H](C)[C@@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJKOYZFVSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 3
- ADUKCCWBEDSMEB-NSHDSACASA-N Prenalterol Chemical compound CC(C)NC[C@H](O)COC1=CC=C(O)C=C1 ADUKCCWBEDSMEB-NSHDSACASA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229960004358 prenalterol Drugs 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- DXPOSRCHIDYWHW-UHFFFAOYSA-N Xamoterol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 DXPOSRCHIDYWHW-UHFFFAOYSA-N 0.000 description 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960001117 clenbuterol Drugs 0.000 description 2
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 229940005501 dopaminergic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960002724 fenoldopam Drugs 0.000 description 2
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 2
- 229940017705 formaldehyde sulfoxylate Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229960001634 ritodrine Drugs 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 229960004928 xamoterol Drugs 0.000 description 2
- XJBCFFLVLOPYBV-UHFFFAOYSA-N zinterol Chemical compound C=1C=C(O)C(NS(C)(=O)=O)=CC=1C(O)CNC(C)(C)CC1=CC=CC=C1 XJBCFFLVLOPYBV-UHFFFAOYSA-N 0.000 description 2
- 229950004209 zinterol Drugs 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical group O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- RLHGFJMGWQXPBW-UHFFFAOYSA-N 2-hydroxy-3-(1h-imidazol-5-ylmethyl)benzamide Chemical compound NC(=O)C1=CC=CC(CC=2NC=NC=2)=C1O RLHGFJMGWQXPBW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- UKTDQTGMXUHPIF-UHFFFAOYSA-N [Na].S(O)(O)=O Chemical compound [Na].S(O)(O)=O UKTDQTGMXUHPIF-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 1
- 229960004253 dexmedetomidine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- SBGKURINHGJRFN-UHFFFAOYSA-N hydroxymethanesulfinic acid Chemical compound OCS(O)=O SBGKURINHGJRFN-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- RVPUETSFKVWTTO-UHFFFAOYSA-N methylaminomethanesulfonic acid Chemical compound CNCS(O)(=O)=O RVPUETSFKVWTTO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229950010998 mivazerol Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- VSVCAMGKPRPGQR-UHFFFAOYSA-N propan-2-one;sulfurous acid Chemical compound CC(C)=O.OS(O)=O VSVCAMGKPRPGQR-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960000720 ritodrine hydrochloride Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960000833 xylometazoline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18406609P | 2009-06-04 | 2009-06-04 | |
| US61/184,066 | 2009-06-04 | ||
| DKPA200900705 | 2009-06-04 | ||
| DKPA200900705 | 2009-06-04 | ||
| CN201080024241XA CN102802668A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080024241XA Division CN102802668A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109397A true CN106109397A (zh) | 2016-11-16 |
Family
ID=41364279
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610726131.7A Pending CN106109397A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
| CN201080024241XA Pending CN102802668A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
| CN201080024234XA Pending CN102497882A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080024241XA Pending CN102802668A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
| CN201080024234XA Pending CN102497882A (zh) | 2009-06-04 | 2010-06-03 | 包含至少一种肾上腺素能化合物的稳定化组合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9155694B2 (enExample) |
| EP (2) | EP2437781B1 (enExample) |
| JP (2) | JP6087145B2 (enExample) |
| KR (2) | KR20120044309A (enExample) |
| CN (3) | CN106109397A (enExample) |
| AU (2) | AU2010255747B2 (enExample) |
| BR (2) | BRPI1011074A2 (enExample) |
| CA (2) | CA2764051A1 (enExample) |
| DK (2) | DK2437781T3 (enExample) |
| ES (2) | ES2432164T3 (enExample) |
| MX (2) | MX2011012735A (enExample) |
| PT (2) | PT2437781E (enExample) |
| RU (2) | RU2527680C2 (enExample) |
| SI (2) | SI2437782T1 (enExample) |
| WO (2) | WO2010139751A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8628805B2 (en) * | 2009-06-04 | 2014-01-14 | Alk Ag | Stabilized composition comprising at least one adrenergic compound |
| CN102525894A (zh) * | 2012-01-04 | 2012-07-04 | 上海禾丰制药有限公司 | 盐酸异丙肾上腺素注射液及其制剂工艺 |
| CN102525893B (zh) * | 2012-01-04 | 2013-11-20 | 上海禾丰制药有限公司 | 盐酸去氧肾上腺素注射液及其制剂工艺 |
| US20150246009A1 (en) * | 2012-10-08 | 2015-09-03 | Wockhardt Limited | Stable injectable pharmaceutical composition of epinephrine or salts thereof |
| TWI641381B (zh) * | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| US12239822B2 (en) | 2013-03-15 | 2025-03-04 | Windgap Medical, Inc. | Portable drug mixing and delivery device and associated methods |
| BR112016007328A2 (pt) * | 2013-10-03 | 2017-08-01 | Imprimis Pharmaceuticals Inc | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
| CN103520096B (zh) * | 2013-10-25 | 2015-02-25 | 成都晶博生物科技有限责任公司 | 一种硫酸特布他林注射液的生产工艺 |
| JP2017503017A (ja) * | 2013-12-18 | 2017-01-26 | ウィンドギャップ メディカル， インコーポレイテッド | 薬物混合および送達システムならびに方法 |
| KR20160104724A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형 |
| UY35988A (es) * | 2014-02-27 | 2015-09-30 | Sint Sa | Proceso para la producción de una solución inyectable de noradrenalina de baja concentración |
| ES2770731T3 (es) | 2014-08-28 | 2020-07-02 | Sun Pharmaceutical Ind Ltd | Forma de dosificación parenteral de norepinefrina |
| AU2015364280A1 (en) * | 2014-12-18 | 2017-07-06 | Windgap Medical, Inc. | Method and compositions for dissolving or solubilizing therapeutic agents |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| US9119876B1 (en) * | 2015-03-13 | 2015-09-01 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| US11517525B2 (en) * | 2015-09-18 | 2022-12-06 | Hikma Pharmaceuticals Usa Inc. | Epinephrine spray formulations |
| US10039710B2 (en) * | 2015-09-18 | 2018-08-07 | Insys Development Company, Inc. | Epinephrine spray formulations |
| EP3503873A4 (en) * | 2016-08-25 | 2020-04-15 | Harrow IP, LLC | EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF |
| RU2635759C1 (ru) * | 2016-09-13 | 2017-11-15 | Интеллег Сосьете Анониме | Фармацевтическая композиция для парентерального введения и способ ее получения |
| US10835503B2 (en) | 2017-01-13 | 2020-11-17 | Teva Pharmaceuticals Usa, Inc. | Pre-filled syringe |
| US20250177328A1 (en) | 2017-01-30 | 2025-06-05 | Nevakar Injectables Inc. | Norepinephrine compositions and methods therefor |
| CA3051467C (en) | 2017-01-30 | 2022-11-29 | Nevakar, Inc | Norepinephrine compositions and methods therefor |
| ES2960528T3 (es) * | 2017-04-17 | 2024-03-05 | Hikma Pharmaceuticals Usa Inc | Formulaciones de epinefrina en aerosol |
| EP3687475A4 (en) * | 2017-09-26 | 2021-07-28 | YS Pharmtech | STABILIZATION OF EPINEPHRIN FORMULATIONS |
| BR112020006950A2 (pt) | 2017-10-10 | 2020-10-06 | Merck Patent Gmbh | composições farmacêuticas injetáveis estabilizadas de l-epinefrina |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| US10653646B2 (en) | 2018-03-23 | 2020-05-19 | Nevakar Inc. | Epinephrine compositions and containers |
| CA3096684A1 (en) | 2018-04-11 | 2019-10-17 | Travis A. Leeah | Ready-to-use liquid reck formulation |
| US10952962B1 (en) | 2018-04-11 | 2021-03-23 | QuVa Pharma, Inc. | Ready to use liquid formulation |
| US10478406B2 (en) | 2019-03-18 | 2019-11-19 | HARC Therapeutics AG | High-pH solid-state epinephrine formulation |
| CN112138250B (zh) * | 2019-06-28 | 2023-04-14 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
| WO2021024237A1 (en) * | 2019-08-08 | 2021-02-11 | Sun Pharmaceutical Industries Limited | Infusion dosage form of norepinephrine |
| USD1004518S1 (en) | 2019-09-09 | 2023-11-14 | Brunswick Corporation | Railing for a marine vessel |
| EP4114336A1 (en) | 2020-03-06 | 2023-01-11 | Baxter International Inc. | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation |
| USD984953S1 (en) | 2021-05-03 | 2023-05-02 | Brunswick Corporation | Safely railing having buoy holder |
| AU2021203856B2 (en) * | 2021-06-10 | 2023-03-09 | Animal Ethics Pty Ltd | Topical anaesthetic composition having improved vasoconstrictor stability |
| AU2023332633A1 (en) * | 2022-08-27 | 2025-04-03 | Biophore India Pharmaceuticals Pvt. Ltd | Trientine liquid dosage forms |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149035A (en) * | 1961-04-28 | 1964-09-15 | Univ California | Stabilization of epinephrine |
| CN101631539A (zh) * | 2006-04-21 | 2010-01-20 | 宝洁公司 | 去氧肾上腺素的组合物和试剂盒 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB425678A (en) | 1933-06-15 | 1935-03-15 | Novocol Chemical Mfg Co Inc | Improvements relating to anesthetics for hypodermic injection |
| US2047144A (en) * | 1934-03-26 | 1936-07-07 | Lilly Co Eli | Stabilized epinephrine-type compound, and process of stabilizing it |
| US2382546A (en) * | 1941-11-03 | 1945-08-14 | Curtis David | Anesthetic solutions |
| US3419035A (en) * | 1965-05-25 | 1968-12-31 | Badger Meter Mfg Co | Air elimination device for liquid transport system |
| CA981182A (en) | 1972-01-07 | 1976-01-06 | Walter A. Borisenok | Stabilization of 1-epinephrine in local anesthetic solutions with a combination of three antioxidants |
| US3966905A (en) * | 1973-05-29 | 1976-06-29 | Barnes-Hind Pharmaceuticals, Inc. | Stabilized catechol amine solutions |
| DD150694A1 (de) | 1980-04-16 | 1981-09-16 | Gisela Raether | Verfahren zur stabilisierung von pharmazeutischen praeparaten mit oxidationsempfindlichen bestandteilen |
| US4734438A (en) | 1983-04-26 | 1988-03-29 | Macri Frank J | Norepinephrine potentiated compositions and method of use |
| AU5680994A (en) | 1992-12-10 | 1994-07-04 | Abbott Laboratories | Stabilized catecholamine solutions |
| JP3535537B2 (ja) * | 1993-04-15 | 2004-06-07 | 日本製薬株式会社 | 静脈注射剤 |
| US6077545A (en) | 1995-10-30 | 2000-06-20 | Matrix Pharmaceuticals, Inc. | Process and composition for therapeutic cisplatin (CDDP) |
| DE69721293T2 (de) | 1996-11-14 | 2004-01-29 | Alza Corp | Einrichtung zur verabreichung von substanzen wie lidocain und epinephrin mit unterstuetzung von elektrischem strom |
| CN100379419C (zh) | 1997-07-11 | 2008-04-09 | 东丽株式会社 | 含有4,5-环氧吗啡喃衍生物的稳定的药物组合物 |
| JP4393641B2 (ja) | 1998-11-26 | 2010-01-06 | 久光製薬株式会社 | イオントフォレーシス用粘着ゲル組成物及びその装置 |
| AU2001294808A1 (en) | 2000-09-29 | 2002-04-08 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
| JP4219932B2 (ja) * | 2003-10-01 | 2009-02-04 | 協和発酵キリン株式会社 | 抗体の安定化方法及び安定化された溶液状抗体製剤 |
| UA71839C2 (uk) * | 2003-12-30 | 2007-06-25 | Товариство З Обмеженою Відповідальністю "Фарм-Стом" | Фармацевтична композиція на основі артикаїну та епінефрину |
| US20050228336A1 (en) | 2004-04-07 | 2005-10-13 | Preston Keusch | Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability |
| US20060129122A1 (en) | 2004-12-06 | 2006-06-15 | Wyrick Ronald E | Method and apparatus for delivering epinephrine |
| WO2007123800A2 (en) | 2006-04-03 | 2007-11-01 | Nutramax Laboratories, Inc. | Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them |
| US20080269347A1 (en) * | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| US8628805B2 (en) | 2009-06-04 | 2014-01-14 | Alk Ag | Stabilized composition comprising at least one adrenergic compound |
-
2010
- 2010-06-03 DK DK10722704.3T patent/DK2437781T3/da active
- 2010-06-03 RU RU2011153403/15A patent/RU2527680C2/ru not_active IP Right Cessation
- 2010-06-03 MX MX2011012735A patent/MX2011012735A/es active IP Right Grant
- 2010-06-03 EP EP10722704.3A patent/EP2437781B1/en active Active
- 2010-06-03 WO PCT/EP2010/057771 patent/WO2010139751A2/en not_active Ceased
- 2010-06-03 MX MX2011012732A patent/MX2011012732A/es active IP Right Grant
- 2010-06-03 CN CN201610726131.7A patent/CN106109397A/zh active Pending
- 2010-06-03 ES ES10722704T patent/ES2432164T3/es active Active
- 2010-06-03 US US13/376,021 patent/US9155694B2/en active Active
- 2010-06-03 PT PT107227043T patent/PT2437781E/pt unknown
- 2010-06-03 KR KR1020117031383A patent/KR20120044309A/ko not_active Ceased
- 2010-06-03 JP JP2012513622A patent/JP6087145B2/ja not_active Expired - Fee Related
- 2010-06-03 DK DK10734927.6T patent/DK2437782T3/da active
- 2010-06-03 JP JP2012513621A patent/JP2012528830A/ja active Pending
- 2010-06-03 ES ES10734927T patent/ES2432241T3/es active Active
- 2010-06-03 SI SI201030408T patent/SI2437782T1/sl unknown
- 2010-06-03 EP EP10734927.6A patent/EP2437782B1/en not_active Not-in-force
- 2010-06-03 PT PT107349276T patent/PT2437782E/pt unknown
- 2010-06-03 CA CA2764051A patent/CA2764051A1/en not_active Abandoned
- 2010-06-03 KR KR1020117031385A patent/KR20120028344A/ko not_active Ceased
- 2010-06-03 WO PCT/EP2010/057772 patent/WO2010139752A2/en not_active Ceased
- 2010-06-03 CN CN201080024241XA patent/CN102802668A/zh active Pending
- 2010-06-03 SI SI201030409T patent/SI2437781T1/sl unknown
- 2010-06-03 CN CN201080024234XA patent/CN102497882A/zh active Pending
- 2010-06-03 AU AU2010255747A patent/AU2010255747B2/en not_active Ceased
- 2010-06-03 BR BRPI1011074A patent/BRPI1011074A2/pt not_active IP Right Cessation
- 2010-06-03 RU RU2011153410/15A patent/RU2527337C9/ru not_active IP Right Cessation
- 2010-06-03 AU AU2010255748A patent/AU2010255748B2/en not_active Ceased
- 2010-06-03 BR BRPI1013019A patent/BRPI1013019A2/pt active Search and Examination
- 2010-06-03 CA CA2764050A patent/CA2764050C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3149035A (en) * | 1961-04-28 | 1964-09-15 | Univ California | Stabilization of epinephrine |
| CN101631539A (zh) * | 2006-04-21 | 2010-01-20 | 宝洁公司 | 去氧肾上腺素的组合物和试剂盒 |
Non-Patent Citations (1)
| Title |
|---|
| H.WOLLMANN ET AL: "Examination of the efficiency of stabilizing agents in Epinephrine model solutions", 《PHARMACY 》 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106109397A (zh) | 包含至少一种肾上腺素能化合物的稳定化组合物 | |
| US8628805B2 (en) | Stabilized composition comprising at least one adrenergic compound | |
| CN101836953B (zh) | 盐酸氨溴索组合物注射液 | |
| WO1991001718A1 (en) | Method of photostabilizing eyewash and photostabilized eyewash | |
| JP6923447B2 (ja) | タペンタドールの非経口投与のための安定な製剤 | |
| CN103340853B (zh) | 含少量抗氧化剂的十八复方氨基酸注射液及其制备方法 | |
| CN107569454B (zh) | 一种盐酸奥洛他定鼻喷雾剂及其制备方法 | |
| CN116270443A (zh) | 富马酸伏诺拉生注射液及其制备方法 | |
| JP5013325B2 (ja) | 液状組成物 | |
| TW202114716A (zh) | 含有對硼苯基丙胺酸之注射液劑之防止析出方法 | |
| DE19756758C1 (de) | Stabilisierte pharmazeutische Zusammensetzung enthaltend Dopamin oder Dobutamin | |
| EP4628082A1 (en) | Pharmaceutical composition of kappa opioid receptor agonist, preparation method therefor, and use thereof | |
| CN106265498A (zh) | 一种新型氢溴酸沃替西汀注射液及其制备方法 | |
| RU2443416C2 (ru) | Капли глазные | |
| HK1162976A1 (en) | Stabilised composition comprising at least one adrenergic compound | |
| HK1162976B (en) | Stabilised composition comprising at least one adrenergic compound | |
| HK1162975B (en) | Stabilised composition comprising at least one adrenergic compound | |
| JP2019529442A (ja) | タペンタドールの非経口投与用安定製剤 | |
| CN107028968A (zh) | 一种含有葡萄糖醛酸吗啡或其可药用盐的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161116 |
|
| WD01 | Invention patent application deemed withdrawn after publication |